专栏名称: 亚盛医药
亚盛医药(6855.HK)是一家立足中国、面向全球的处于临床阶段的原创新药研发企业,专注于在肿瘤、乙肝及与衰老相关的疾病等治疗领域开发创新药物。公司拥有自主研发的蛋白-蛋白相互作用靶向药物设计平台,在细胞凋亡领域的研发颇为突出。
目录
相关文章推荐
指尖新闻沈阳晚报  ·  消失20年的“留级”“跳级”又悄悄回来了? ·  昨天  
鮀浦微帮  ·  寒假即将结束,2025汕头中考时间出炉! ·  2 天前  
鮀浦微帮  ·  寒假即将结束,2025汕头中考时间出炉! ·  2 天前  
厦门网  ·  定了!福建省教育厅最新公布! ·  2 天前  
第1眼新闻  ·  @学生们 ... ·  3 天前  
51好读  ›  专栏  ›  亚盛医药

EHA2024|Updated Data of Lisaftoclax in R/R MM and AL Amyloidosis

亚盛医药  · 公众号  ·  · 2024-06-18 08:03

正文

Ascentage Pharma (6855.HK) announced today that it has released updated data of the Bcl-2 inhibitor lisaftoclax (APG-2575), one of the company’s key drug candidates, combined with novel therapeutic regimens in patients with relapsed/refractory (R/R) multiple myeloma (MM) or immunoglobulin light-chain (AL) amyloidosis, in a poster presentation at the 2024 European Hematology Association Hybrid Congress (EHA 2024), taking place in Madrid, Spain.

Building on results from the study released for the first time at the 2023 American Society of Hematology Annual Meeting, the updated data presented at EHA 2024 continued to show impressive efficacy and favorable safety of lisaftoclax-based combinations, particularly the combination with pomalidomide and dexamethasone in R/R MM . Moreover, the study reported an incidence of Grade 3 or higher treatment-related neutropenia of 14.3%, which underscored the regimens’ potential in offering patients a safe new treatment option.


Prof. Sikander Ailawadhi

the principal investigator of the study

Mayo Clinic

This is a study of lisaftoclax combined with novel therapeutic regimens in patients with R/R MM or AL amyloidosis. From the primary analysis, it demonstrated that lisaftoclax + pomalidomide in R/R MM could achieve ≥very good partial response (VGPR) rate of 33.3%, and higher VGPR along with increasing lisaftoclax dosage. Moreover, lisaftoclax based therapy in both R/R MM and amyloidosis is very well tolerated with Grade 3/4 neutropenia of 14.3%. This convincing data could provide an alternative treatment option to patients with MM and amyloidosis.

Dr. Yifan Zhai

Chief Medical Officer of Ascentage Pharma

It is our pleasure to release the updated data of lisaftoclax in patients with R/R MM or AL amyloidosis at this year’s EHA Hybrid Congress. These data underscore the outstanding safety and efficacy profiles of the combination therapies, once again demonstrating these regimens’ global best-in-class potential. We will actively advance this clinical development program to bring patients a safe and effective new treatment option as soon as possible.


The EHA Hybrid Congress is the largest gathering of the hematology field in Europe. It showcases the most cutting-edge research and state-of-the-art innovative therapies, attracting over 10,000 clinical experts and researchers from more than 100 countries every year. This year, in addition to the latest data of lisaftoclax, Ascentage Pharma also released those of the third-generation BCR-ABL1 inhibitor olverembatinib (HQP1351) and the EED inhibitor APG-5918.



Highlights of the data on lisaftoclax presented at EHA 2024 are as follows:



Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (Pts) with Relapsed or Refractory (R/R) Multiple Myeloma (MM) or Immunoglobulin Light-Chain (AL) Amyloidosis


Abstract#

P917

Presentation Type

Poster presentation

Topic

14. Myeloma and other monoclonal gammopathies – Clinical

Date & Time

Friday June 14, 2024, 18:00 - 19:00 CEST

Presenting Author

Dr. Sikander Ailawadhi,

Mayo Clinic Florida

Highlights

Background : R/R MM is incurable, with virtually inevitable relapse without appropriate therapeutic intervention. AL amyloidosis is a rare disease that may cause serious organ damage or death. Lisaftoclax is a novel, potent, selective BCL-2 inhibitor with clinical benefits in hematologic malignancies and solid tumors and a low reported incidence of adverse events (AEs).

Introduction : The aim of this multicenter study was to evaluate the safety and efficacy of lisaftoclax combined with pomalidomide and dexamethasone (Arms A and C) or daratumumab, lenalidomide, and dexamethasone (Arm B) in patients with R/R MM (Arms A and B) or R/R AL amyloidosis (Arm C).

Patient enrollment and methods : Patients with an Eastern Cooperative Oncology Group (ECOG) performance status≤2 were administered lisaftoclax daily in repeated 28-day cycles. Pomalidomide, daratumumab, and lenalidomide were administered per label use. Dexamethasone was administered at 40 mg/day, and patients aged>75 were administered at the reduced dose of 20 mg/day.

- As of January 25, 2024, 44 patients that included 36 patients with R/R MM and 8 patients with R/R AL amyloidosis were enrolled in the 3 arms of the study (Arms A, B, and C) to receive lisaftoclax at various doses.

- The median (range) age of patients was 70.5 (24-88) years, 68.2% were male, and 65.9% were older than 65 years.

- The median (range) number of lines of prior therapies was 3 (1-19), median (range) time from diagnosis to the first dose of study drug was 5.5 (1-29) years, and median (range) number of treatment cycles was 4 (1-26).

Efficacy results

- In Arm A, 27 patients with R/R MM were efficacy evaluable. Among them, 10 had partial response (PR), 7 had very good PR (VGPR), and 2 had complete response (CR). The overall response rate (ORR [PR+VGPR+CR]) was 70.4%.

- In Arm B, 2 patients with R/R MM achieved CR.

- In Arm C, 7 patients with R/R AL amyloidosis were efficacy evaluable, and the ORR was 85.7% (4 VGPRs, 2 CR).

Safety results

- Of the 42 patients included in safety analysis, 10 patients experienced Grade ≥3 treatment-related adverse events (TRAEs), including neutropenia (14.3%), febrile neutropenia (2.4%). 3 patients experienced serious TRAEs that included febrile neutropenia, acute kidney injury, and diarrhea with electrolyte imbalance (1 each).

- A total of 24 patients discontinued treatment because of disease progression (n=15), treatment-emergent AE (TEAE, n=3), nonadherence (n=1), or investigator/patient decision (n=5).

Conclusions

Lisaftoclax plus novel therapeutic regimens was well tolerated and demonstrated preliminary antitumor activity in patients with either R/R MM or AL amyloidosis.








请到「今天看啥」查看全文